Clinical Trials Browser

Phase 2 × INDUSTRY × gilteritinib × Clear all

NCT02927262 2024-11-26

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Phase 2 Completed

98 enrolled 17 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute